CommIT

<p>MIAMI, Sept. 04, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to a new non-executive employee in the aggregate amount of 23,764 shares of restricted stock (the “Inducement Grants”) outside of InspireMD’s 2021 Equity Incentive Plan, with a grant date as of September 2, 2026, as an inducement material to the non-executive employee entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).</p>

Sep 4, 2026

<p>PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a shared commitment with the Trump Administration to lower the cost of select medicines for American patients covered by Medicaid. When finalized, this agreement will support continued investment in scientific innovation and pharmaceutical manufacturing capabilities.  <br />  <br />“Teva appreciates the opportunity to work with President Trump and his Administration to expand access and affordability for patients today while enabling continued investment in medicines patients need tomorrow,” said Chris Fox, President, Teva USA. “Teva built its business around delivering affordable medicines to Americans, and we share the Administration’s commitment to improve access to more affordable medicines while investing in scientific innovation and domestic manufacturing capabilities in the U.S.” <br />                                                                                                 <br />Teva remains in active discussions with the Trump Administration to strike a deal anchored in all four of the President’s drug pricing priorities. If an agreement is reached, Teva would align U.S. Medicaid pricing for select medicines with pricing in leading developed markets through the GENEROUS (GENErating cost Reductions fOr U.S. Medicaid) framework. The agreement also would include a prospec…

Aug 31, 2026

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQMWVqOUhRYTd2SEZvWjhhOWlaSUJLVzhtWlBVNDhhUHlYaGx4UGZ6WVY1TUFrTTVqMENIWjByQVlxUTFLQ0NCWW9RQUxPOS1sR2s1N0Q4VjdFbDIzZ1BHRkxfb2xReFVKSV8wRS0zbXBRWEpvLTFxYWZoSlFWRm5ieHZHYW4yaGYtYllIQUM2TVJ4ZFQ2WXgzR2gtWU9BWXE0YzBiaTNQQVJheGF5UHdSVnNmMGd2RFA3TkFrMFd3?oc=5" target="_blank">Police chief meets election committee heads to discuss AI and other threats</a>&nbsp;&nbsp;<font color="#6f6f6f">The Times of Israel</font>

Aug 13, 2026

<p>MIAMI, Aug. 07, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to a new non-executive employee in the aggregate amount of 221,666 shares of restricted stock (the “Inducement Grants”) outside of InspireMD’s 2021 Equity Incentive Plan, with a grant date as of August 3, 2026, as an inducement material to the non-executive employee entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).</p>

Aug 7, 2026

<p align="justify">TEL AVIV, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that post-hoc data from its Phase 2 clinical trial of EB613 (oral PTH(1-34) tablet) has been selected for two presentations including the Plenary Poster Presentation at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting, taking place October 9–12, 2026, at the John B. Hynes Veterans Memorial Convention Center in Boston, Massachusetts. Plenary Posters are highly ranked poster presentations selected by the ASBMR program committee to be presented at the Welcome Reception and Plenary Poster Session of the ASBMR 2026 Annual Meeting.</p>

Aug 4, 2026

<p align="justify">TEL AVIV, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that post-hoc data from its Phase 2 clinical trial of EB613 (oral PTH(1-34) tablet) has been selected for two presentations including the Plenary Poster Presentation at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting, taking place October 9–12, 2026, at the John B. Hynes Veterans Memorial Convention Center in Boston, Massachusetts. Plenary Posters are highly ranked poster presentations selected by the ASBMR program committee to be presented at the Welcome Reception and Plenary Poster Session of the ASBMR 2026 Annual Meeting.</p>

Aug 4, 2026

Checkmarx launches self-healing application security agents that autonomously detect, fix and verify vulnerabilities before code is committed.

Jul 14, 2026

<a href="https://news.google.com/rss/articles/CBMie0FVX3lxTE5lMkhPVWczZy0yTWVRb2x0NkZMYXdxRVVzUlJVZGN3NjlQZVUxNlZYWERsY2ItZUNXZWlIZnhGNGkyazlkV0QwckJVelZaTWotMEpVbkhaUVpRd0JwLXJncVY3bnNFdzZWSVg1amhCcXozQ3BSa01jZ2VvQQ?oc=5" target="_blank">Naftali Bennett forms AI advisory committee in bid to boost Israel's tech policy</a>&nbsp;&nbsp;<font color="#6f6f6f">The Jerusalem Post</font>

Jun 18, 2026

<a href="https://news.google.com/rss/articles/CBMiY0FVX3lxTE9OZFBhVXU4UmI3M2hwdGRpSUhZTkJCVEJ6ZWRnNTlNWXhXNVRPemJUemVvdUdiQUJGWnotb0pVTnR0Y2FVQWtpRXhBbW1laEpldHcxRHFFN0dYYjhQTDZfVi1RVQ?oc=5" target="_blank">Israel’s Commit acquires Africa-focused tech recruiter Savannah in strategic talent expansion</a>&nbsp;&nbsp;<font color="#6f6f6f">Ynetnews</font>

Jan 18, 2026

<a href="https://news.google.com/rss/articles/CBMiaEFVX3lxTE1kNF93blBPcUR2ZFRCWm04MmF3SkRsLXAwd3ItaVlyUFo4ZVMydERVYjBkdVRLSlV6VjBOQThQMDctRzhLSU9COUFLZUpMY0RyM2lvRUI4SlppWHBxZlpiNkhqSWk0T3Ja?oc=5" target="_blank">Commit acquires Savannah to enter Africa’s growing software talent market</a>&nbsp;&nbsp;<font color="#6f6f6f">CTech</font>

Jan 18, 2026